GlassScriptPhysician profile
George A Gamouras
NPI 1508833757
$3,932.44
in general payments reported to CMS, 2019-2025
26 companies · $440 in 2025
The $440 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $475 · 2021: $557 · 2022: $492 · 2023: $730 · 2024: $793 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $716.47 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.80 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $365.51 | 2021-2024 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $345.65 | 2022-2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $312.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $260.54 | 2019-2024 | Farxiga, Andexxa |
| Pfizer INC. | $212.16 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.58 | 2023-2025 | |
| Edwards Lifesciences Corporation | $189.61 | 2020-2024 | Pascal, Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $130.35 | 2022-2025 | Eliquis |
| Amgen INC. | $115.07 | 2019-2025 | Repatha |
| Chiesi USA, INC. | $91.61 | 2019-2023 | Kengreal |
| Abiomed | $71.29 | 2020-2025 | |
| Abbott Laboratories | $69.57 | 2019-2024 | I-Stat |
| Cvrx, INC. | $51.12 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $49.84 | 2023 | Cardiva Vascade 6/7f Vcs |
| Kowa Pharmaceuticals America, INC. | $40.75 | 2019-2020 | |
| Philips North America LLC | $37.33 | 2024 | (Cm9) Amb Mon & Diag Und |
| Bridgebio Pharma, INC. | $36.19 | 2025 | Attruby |
| Astellas Pharma US INC | $35.37 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $27.34 | 2024 | Optimizer |
| Heartflow, INC. | $22.78 | 2024 | |
| Glaxosmithkline, LLC. | $22.44 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $18.78 | 2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $17.01 | 2025 | Assure Wcd |
| Penumbra, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Gamouras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.